Literature DB >> 17921346

IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes.

Yongqing Li1, Cassian Yee.   

Abstract

Efforts to reproducibly isolate tumor antigen-specific T cells from patients would be facilitated by removing immunoregulatory barriers. Using a human model for eliciting T-cell responses to tumor-associated antigens, we develop a novel strategy that eliminates nearly all Foxp3-expressing cells through the combination of CD25 depletion and IL-21 treatment resulting in a more than 150-fold decrease in Foxp3(+) cells to virtually undetectable levels and a more than 200-fold increase in antigen-specific cytotoxic T lymphocytes (CTLs). The extent of Foxp3 elimination and degree of expansion of antigen-specific CTLs shown in this study have not previously been achievable and are unique to IL-21. We demonstrate for the first time a possible mechanism for IL-21-mediated expansion of antigen-specific CTLs that involves suppression of Foxp3-expressing cells and reversal of inhibition to tumor-associated antigen-specific CTL generation in vitro. Taken together, the combination of CD25 depletion and IL-21 exposure, by releasing regulatory constraints, leads to markedly enhanced CTL induction and represents a robust strategy for the ex vivo generation of antigen-specific T cells for adoptive cellular therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17921346      PMCID: PMC2200808          DOI: 10.1182/blood-2007-05-089375

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.

Authors:  J Steitz; J Brück; J Lenz; J Knop; T Tüting
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

2.  Autoreactive T cells in healthy individuals.

Authors:  Nancy A Danke; David M Koelle; Cassian Yee; Sucheta Beheray; William W Kwok
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

3.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

Authors:  J Shimizu; S Yamazaki; S Sakaguchi
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

4.  Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function.

Authors:  J Parrish-Novak; S R Dillon; A Nelson; A Hammond; C Sprecher; J A Gross; J Johnston; K Madden; W Xu; J West; S Schrader; S Burkhead; M Heipel; C Brandt; J L Kuijper; J Kramer; D Conklin; S R Presnell; J Berry; F Shiota; S Bort; K Hambly; S Mudri; C Clegg; M Moore; F J Grant; C Lofton-Day; T Gilbert; F Rayond; A Ching; L Yao; D Smith; P Webster; T Whitmore; M Maurer; K Kaushansky; R D Holly; D Foster
Journal:  Nature       Date:  2000-11-02       Impact factor: 49.962

5.  Phenotypic analysis of antigen-specific T lymphocytes.

Authors:  J D Altman; P A Moss; P J Goulder; D H Barouch; M G McHeyzer-Williams; J I Bell; A J McMichael; M M Davis
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

6.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

7.  Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma.

Authors:  Neil A Marshall; Linsey E Christie; Laura R Munro; Dominic J Culligan; Peter W Johnston; Robert N Barker; Mark A Vickers
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

Review 8.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

Authors:  Shimon Sakaguchi
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

9.  Cancer antigens: immune recognition of self and altered self.

Authors:  A N Houghton
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

10.  Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.

Authors:  Mary Jo Turk; José A Guevara-Patiño; Gabrielle A Rizzuto; Manuel E Engelhorn; Shimon Sakaguchi; Alan N Houghton
Journal:  J Exp Med       Date:  2004-09-20       Impact factor: 14.307

View more
  60 in total

Review 1.  Multiple vaccinations: friend or foe.

Authors:  Sarah E Church; Shawn M Jensen; Christopher G Twitty; Keith Bahjat; Hong-Ming Hu; Walter J Urba; Bernard A Fox
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.

Authors:  Jungsun Park; Amjad H Talukder; Seon A Lim; Kwanghee Kim; Ke Pan; Brenda Melendez; Sherille D Bradley; Kyle R Jackson; Jahan S Khalili; Junmei Wang; Caitlin Creasy; Bih-Fang Pan; Scott E Woodman; Chantale Bernatchez; David Hawke; Patrick Hwu; Kyung-Mi Lee; Jason Roszik; Gregory Lizée; Cassian Yee
Journal:  Cancer Immunol Res       Date:  2017-06-19       Impact factor: 11.151

3.  Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy.

Authors:  Matthias Wölfl; Katharina Merker; Henner Morbach; Stefaan W Van Gool; Matthias Eyrich; Philip D Greenberg; Paul G Schlegel
Journal:  Cancer Immunol Immunother       Date:  2010-10-24       Impact factor: 6.968

Review 4.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 5.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

6.  Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I.

Authors:  Aude G Chapuis; Olga K Afanasiev; Jayasri G Iyer; Kelly G Paulson; Upendra Parvathaneni; Joo Ha Hwang; Ivy Lai; Ilana M Roberts; Heather L Sloan; Shailender Bhatia; Kendall C Shibuya; Ted Gooley; Cindy Desmarais; David M Koelle; Cassian Yee; Paul Nghiem
Journal:  Cancer Immunol Res       Date:  2014-01       Impact factor: 11.151

7.  Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors.

Authors:  Joshua D Brody; Matthew J Goldstein; Debra K Czerwinski; Ronald Levy
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

8.  IL-21 receptor signalling partially mediates Th2-mediated allergic airway responses.

Authors:  S Lajoie; I Lewkowich; N S Herman; A Sproles; J T Pesce; T A Wynn; M J Grusby; Q Hamid; M Wills-Karp
Journal:  Clin Exp Allergy       Date:  2014-07       Impact factor: 5.018

9.  Loss of parity between IL-2 and IL-21 in the NOD Idd3 locus.

Authors:  Helen M McGuire; Alexis Vogelzang; Natasha Hill; Malin Flodström-Tullberg; Jonathan Sprent; Cecile King
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-30       Impact factor: 11.205

10.  Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells.

Authors:  Giuseppina Bonanno; Andrea Mariotti; Annabella Procoli; Maria Corallo; Giovanni Scambia; Luca Pierelli; Sergio Rutella
Journal:  BMC Immunol       Date:  2009-08-27       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.